{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:36:08Z","timestamp":1770320168177,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To elicit a robust immune response, an adjuvant can be combined with the antigen in influenza vaccine formulations. In this study, we evaluated the dose-sparing effect and safety of a squalene-based oil-in-water nanoemulsion (NE) adjuvant formulated with a cell culture-derived quadrivalent influenza vaccine. Immune responses-including anti-HA IgG antibody levels and hemagglutination inhibition (HAI) titers-were assessed, along with protection against a homologous challenge with influenza B virus (strain B\/Maryland\/15\/2016 B\/Victoria). We also investigated the influence of antigen dose on vaccine-induced immunity and the passive protection conferred to offspring via maternal antibody transfer. The NE adjuvant elicited strong anti-HA antibody responses in young adult mice, and these antibodies were effectively transferred from immunized mothers to their offspring. Furthermore, offspring born to NE-immunized mothers were protected against influenza virus challenge. Collectively, our results indicate that the NE formulation induces potent influenza-specific immune responses with dose-sparing effects and enables maternal transfer of protective immunity. These findings support the potential of NE as an effective adjuvant for MDCK cell-based influenza subunit vaccines. Importance. This study demonstrates that a squalene-based nanoemulsion (NE) adjuvant significantly enhances the immunogenicity and dose-sparing capacity of cell culture-derived quadrivalent influenza vaccines. Key advances include: (1) NE-adjuvanted vaccines achieved a remarkable 125-fold antigen dose reduction while maintaining antibody titers comparable to high-dose formulations, addressing critical challenges in pandemic preparedness; (2) NE induced robust humoral and cellular immunity, including elevated anti-HA IgG (10-fold increase vs. non-adjuvanted vaccine), improved HI titers, and enhanced IFN-\u03b3\/CD8\u2009+\u2009T-cell responses; (3) Unique maternal-offspring protection was demonstrated, with transferred maternal antibodies conferring 100% survival in offspring against viral challenge. These findings position NE as an effective adjuvant technology that simultaneously optimizes antigen use and broadens immune protection across age groups.<\/jats:p>","DOI":"10.1186\/s12985-025-03006-z","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:46:45Z","timestamp":1769755605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The nanoemulsion adjuvant provides antigen dose-sparing effects and enhances maternal passive immune protection for the cell-cultured quadrivalent influenza virus subunit vaccine"],"prefix":"10.1186","volume":"23","author":[{"given":"Yutian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbo","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dapeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"1","key":"3006_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","volume":"71","author":"LA Grohskopf","year":"2022","unstructured":"Grohskopf LA, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022;71(1):1\u201328.","journal-title":"MMWR Recomm Rep"},{"issue":"5919","key":"3006_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/303706a0","volume":"303","author":"GC Schild","year":"1983","unstructured":"Schild GC, et al. Evidence for host-cell selection of influenza virus antigenic variants. Nature. 1983;303(5919):706\u20139.","journal-title":"Nature"},{"key":"3006_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6020019","volume":"6","author":"AT Harding","year":"2018","unstructured":"Harding AT, Heaton NS. Efforts to improve the seasonal influenza vaccine. Vaccines. 2018;6:2.","journal-title":"Vaccines"},{"issue":"Suppl 1","key":"3006_CR4","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1093\/ofid\/ofy209.164","volume":"5","author":"S Rajaram","year":"2018","unstructured":"Rajaram S, et al. 2556. Retrospective evaluation of mismatch from Egg-Based isolation of influenza strains compared with Cell-Based isolation and the possible implications for vaccine effectiveness. Open Forum Infect Dis. 2018;5(Suppl 1):S69\u201369.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"3006_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3390\/vaccines9111255","volume":"9","author":"R de Ortiz","year":"2021","unstructured":"de Ortiz R et al. Estimation of reduction in influenza vaccine effectiveness due to Egg-Adaptation Changes-Systematic literature review and expert consensus. Vaccines (Basel). 2021;9(11):1255.","journal-title":"Vaccines (Basel)"},{"issue":"12 Suppl 2","key":"3006_CR6","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","volume":"224","author":"T Becker","year":"2021","unstructured":"Becker T, et al. Influenza vaccines: successes and continuing challenges. J Infect Dis. 2021;224(12 Suppl 2):S405\u201319.","journal-title":"J Infect Dis"},{"issue":"10","key":"3006_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac497","volume":"9","author":"SA Richard","year":"2022","unstructured":"Richard SA, et al. Influenza vaccine effectiveness: analysis of the impact of repeated vaccinations in military health system beneficiaries. Open Forum Infect Dis. 2022;9(10):ofac497.","journal-title":"Open Forum Infect Dis"},{"key":"3006_CR8","doi-asserted-by":"publisher","first-page":"662218","DOI":"10.3389\/fimmu.2021.662218","volume":"12","author":"S Barman","year":"2021","unstructured":"Barman S, et al. Precision vaccine development: cues from natural immunity. Front Immunol. 2021;12:662218.","journal-title":"Front Immunol"},{"issue":"1","key":"3006_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-0626-6","volume":"27","author":"JR Chen","year":"2020","unstructured":"Chen JR, et al. Better influenza vaccines: an industry perspective. J Biomed Sci. 2020;27(1):33.","journal-title":"J Biomed Sci"},{"issue":"3","key":"3006_CR10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/vaccines11030695","volume":"11","author":"M Kozak","year":"2023","unstructured":"Kozak M, Hu J. The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development. Vaccines. 2023;11(3):695. https:\/\/doi.org\/10.3390\/vaccines11030695.","journal-title":"Vaccines"},{"issue":"11","key":"3006_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/17425255.2020.1807936","volume":"16","author":"E Sasaki","year":"2020","unstructured":"Sasaki E, Hamaguchi I, Mizukami T. Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design. Expert Opin Drug Metab Toxicol. 2020;16(11):1051\u201361.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3006_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/vaccines11010052","volume":"11","author":"S Rockman","year":"2022","unstructured":"Rockman S, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines. 2022;11(1):52. https:\/\/doi.org\/10.3390\/vaccines11010052.","journal-title":"Vaccines"},{"key":"3006_CR13","doi-asserted-by":"publisher","first-page":"1002286","DOI":"10.3389\/fimmu.2022.1002286","volume":"13","author":"MLL Myers","year":"2022","unstructured":"Myers MLL, et al. Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus. Front Immunol. 2022;13:1002286. https:\/\/doi.org\/10.3389\/fimmu.2022.1002286.","journal-title":"Front Immunol"},{"issue":"3","key":"3006_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.36233\/0372-9311-244","volume":"99","author":"IV Krasilnikov","year":"2022","unstructured":"Krasilnikov IV, et al. Preclinical study of immunogenicity of adjuvanted quadrivalent subunit influenza vaccine. J Microbiol Epidemiol Immunobiol. 2022;99(3):300\u20138.","journal-title":"J Microbiol Epidemiol Immunobiol"},{"issue":"6","key":"3006_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran B, P SA, O\u2019Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454\u201375.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3006_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/oxfordjournals.bmb.a071545","volume":"35","author":"CW Potter","year":"1979","unstructured":"Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69\u201375.","journal-title":"Br Med Bull"},{"issue":"6","key":"3006_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/0264-410X(95)00240-2","volume":"14","author":"DA Higgins","year":"1996","unstructured":"Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine. 1996;14(6):478\u201384.","journal-title":"Vaccine"},{"issue":"2","key":"3006_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10157-012-0696-1","volume":"17","author":"J Son","year":"2013","unstructured":"Son J, et al. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A\/H1N1 vaccine in dialysis patients. Clin Exp Nephrol. 2013;17(2):275\u201383.","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"3006_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1086\/590913","volume":"198","author":"K Levie","year":"2008","unstructured":"Levie K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis. 2008;198(5):642\u20139.","journal-title":"J Infect Dis"},{"issue":"16","key":"3006_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0264-410X(97)00115-1","volume":"15","author":"DM Cataldo","year":"1997","unstructured":"Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine. 1997;15(16):1710\u20135.","journal-title":"Vaccine"},{"issue":"8","key":"3006_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","volume":"15","author":"CM Trombetta","year":"2016","unstructured":"Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15(8):967\u201376.","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"3006_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4161\/hv.22908","volume":"9","author":"RJ Cox","year":"2013","unstructured":"Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother. 2013;9(2):405\u20138.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"3006_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.it.2014.06.004","volume":"35","author":"NL La Gruta","year":"2014","unstructured":"La Gruta NL, Turner SJ. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol. 2014;35(8):396\u2013402.","journal-title":"Trends Immunol"},{"key":"3006_CR24","doi-asserted-by":"publisher","first-page":"959379","DOI":"10.3389\/fimmu.2022.959379","volume":"13","author":"Y Janssens","year":"2022","unstructured":"Janssens Y, et al. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation. Front Immunol. 2022;13:959379. https:\/\/doi.org\/10.3389\/fimmu.2022.959379.","journal-title":"Front Immunol"},{"key":"3006_CR25","doi-asserted-by":"publisher","first-page":"984642","DOI":"10.3389\/fimmu.2022.984642","volume":"13","author":"G Waerlop","year":"2022","unstructured":"Waerlop G, et al. Harmonization and qualification of an IFN-? enzyme-linked immunospot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. Front Immunol. 2022;13:984642. https:\/\/doi.org\/10.3389\/fimmu.2022.984642.","journal-title":"Front Immunol"},{"issue":"5","key":"3006_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/21645515.2019.1565269","volume":"15","author":"E Gianchecchi","year":"2019","unstructured":"Gianchecchi E, Torelli A, Montomoli E. The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity. Hum Vaccin Immunother. 2019;15(5):1021\u201330.","journal-title":"Hum Vaccin Immunother"},{"key":"3006_CR27","first-page":"130","volume":"42","author":"G Ott","year":"2013","unstructured":"Ott G, Radhakrishnan R, Fang J-H, Hora M. The adjuvant MF59: a 10-year perspective. Methods Mol Med. 2013;42:130\u201345.","journal-title":"Methods Mol Med"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-03006-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03006-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03006-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:17:49Z","timestamp":1770279469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-025-03006-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-03006-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in accordance with the guidelines of the \u201cNational Animal Management Regulations of China\u201d and approved by the Institutional Animal Care and Use Committee of Changchun Institute of Biological Products (permit number: CCIBP202302-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}